Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?.
- Author:
George GALYFOS
1
;
Argyri SIANOU
Author Information
- Publication Type:Review
- Keywords: Stroke; Secondary prevention; Guideline
- MeSH: Cardiovascular Diseases; Intermittent Claudication; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Secondary Prevention*; Stroke*
- From:Vascular Specialist International 2017;33(3):89-92
- CountryRepublic of Korea
- Language:English
- Abstract: Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol’s action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.
